The approved strengths are 1.5 mg, 3 mg, 6 mg, and 9 mg, and the product is therapeutically equivalent to Janssen's Invega.

Alembic Pharma gets US FDA approval for paliperidone ER tablets: Our Bureau, Bengaluru Monday, September 30, 2024, 11:30 Hrs [IST] Alembic Pharmaceuticals has received final appro ...

The FDA has approved Alembic's generic Albenza and generic Invega. Alembic has received The Food and Drug Administration’s ...

Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of Paliperidone extended-release tablets indicated for the treatment ...

On 26 September 2024, Bristol Myers Squibb (BMS) announced that the US Foof and Drug Administration approved Cobenfy ...

Vadodara: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug ...

With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in ...

Alembic Pharma Ltd. has received an establishment inspection report from the US Food and Drug Administration for its facility in Panelav, Gujarat. The EIR was issued post the last inspection of the ...

Vadodara: Alembic Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US ...

INVEGA HAFYERA contains the active ingredient paliperidone palmitate. INVEGA HAFYERA is used to treat schizophrenia in adults (18 years of age and older). For more information, see Section 1.

A key rival could be Johnson & Johnson's recently-approved Invega Hafyera (paliperidone), which only needs to be administered twice-yearly, as well as J&J's older monthly and three-monthly ...